Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights

Basit Öğe Kaydı
dc.authoridramasami, ponnadurai/0000-0002-7272-3561
dc.authoridParlak, Cemal/0000-0002-6115-6098
dc.authorscopusid8902134000
dc.authorscopusid16318739400
dc.authorscopusid57201687370
dc.authorscopusid26656028100
dc.authorscopusid6508051428
dc.authorwosidAlver, özgür/AAE-1342-2022
dc.contributor.authorParlak, Cemal
dc.contributor.authorAlver, Ozgur
dc.contributor.authorOuma, Cecil N. M.
dc.contributor.authorRhyman, Lydia
dc.contributor.authorRamasami, Ponnadurai
dc.date.accessioned2023-01-12T19:58:48Z
dc.date.available2023-01-12T19:58:48Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractThe proverb Old is gold is applicable in drug discovery and the proverb All that Glitters is not Gold is also appropriate. In the COVID-19 era, there has been a race for drugs to be effective against SARS-CoV-2. There are reports about the uses of Remdesivir and Favipiravir as existing antivirals against virus but none have been conclusive so far. In the attempts for innovations, the combination of drugs is also undertrials. Therefore, we used the densityfunctional theory method and quantum theory of atoms in moleculesto investigate drug-drug interactions involving Remdesivir and Favipiravir. The computed parameters were related to the antiviral actions of both drugs together. The results indicate enhanced antiviral activity and it will be worthy to consider additional investigations with the combination of these two drugs.en_US
dc.identifier.doi10.1055/a-1585-1323
dc.identifier.endpage40en_US
dc.identifier.issn2194-9379
dc.identifier.issn2194-9387
dc.identifier.issue1en_US
dc.identifier.pmid34535038en_US
dc.identifier.scopus2-s2.0-85115825958en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage34en_US
dc.identifier.urihttps://doi.org/10.1055/a-1585-1323
dc.identifier.urihttps://hdl.handle.net/11454/77027
dc.identifier.volume72en_US
dc.identifier.wosWOS:000696672900002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGeorg Thieme Verlag Kgen_US
dc.relation.ispartofDrug Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRemdesiviren_US
dc.subjectFavipiraviren_US
dc.subjectDrug-drug interactionen_US
dc.subjectDFTen_US
dc.subjectQTAIMen_US
dc.subjectAtomsen_US
dc.subjectDescriptorsen_US
dc.subjectMechanismen_US
dc.subjectPristineen_US
dc.subjectT-705en_US
dc.titleCan the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insightsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu